« Return to News | Drug Sponsors

EMD Serano's Firouz steps down

Friday, May 20, 2011 12:37 PM

President and CEO Fereydoun Firouz of Mass.-based EMD Serono, an affiliate of Merck, has resigned from his position following two decades of dedicated service to EMD Serono. Firouz has independently decided to pursue other professional opportunities. James Hoyes, who is currently chief commercial officer at EMD Serono, will serve as acting head of the organization on an ad interim basis.

Firouz began his career with Serono in 1989 as a government affairs associate in the company's Washington, DC office.  He progressed into positions of increasing responsibility before taking the role of president and CEO of U.S. operations in 2003. During his tenure as president and CEO of EMD Serono, Firouz tripled the revenues and capabilities of the U.S. organization, instilling pride, integrity and purpose amongst the employee base with a focus on advancing science and medicine, impacting the health of patients, being a leader, and contributing to society in a meaningful way.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.